Complete decongestive therapy (CDT) in lymphoedema/phlebolymphoedema

Summary

In contrast to the scientifically recognised status of CDT (phases I + II) as first-line treatment in primary and secondary lymphoedema, initial decongestion of phlebolymphoedema (stages II + III a/b of CVI according to Widmer/CEAP IV-VI) on an outpatient basis is largely unknown. As prevention of the further progression of venous lymphostatic disease and the development of gravitational ulcer, the German Federal Committee of Physicians and Health Insurers (Bundesausschuss Ärzte-Krankenkassen) incorporated the decongestive phase (phase I of CDT) into the valid Federal Joint Committee Remedies Directive (Heilmittelrichtlinien), sections LY 1 and LY 2, as early as a decade ago. Provision of the indispensable medical compression stocking is only advisable after performing the daily phase I CDT for an average of 10 times up to a maximum of 15 times. Consistent further treatment as phase II CDT (maintenance phase) is only necessary in exceptional cases following corresponding medical findings.

Keywords

Complete decongestive therapy (CDT) - prevention of progression of CVI - phlebolymphostatic oedema - medical compression stocking

• References

• 1 Haghighat S. et al. Predictive Factors of Response to Phase I Complete Decongestive Therapy in upper extremity Lymphedema following breast carcinoma in Iran. Lymphology 2013; 46 (Suppl. 02) 97-104.
• 2 Schad H. Gilt die Starling’sche Hypothese noch?. LymphForsch 2009; 13: 71-77.
• 3 Weissleder H, Schuchhardt C. Erkrankungen des Lymphgefäßsystems. Essen: Viavital-Verlag; 2011: 424.